Insights on Clinical Trials

  1. Why Your Bioanalysis Bottleneck Is Costing You More Than You Think 3/9/2026

    This piece explains why turnaround time is a strategic variable, where speed is truly achievable, and how automation reshapes the path from sample submission to decision‑ready data.

  2. Inside SynaptixBio's Mission To Develop A Therapy For H-ABC 3/9/2026

    SynaptixBio's Dr. Dan Williams discusses the company’s effort to develop an antisense oligonucleotide therapy that silences the mutant TUBB4A gene in the ultra-rare leukodystrophy H-ABC, highlighting the scientific, regulatory, and funding challenges of advancing treatments for extremely small patient populations.

  3. CNS Trials Are Difficult — Do They Have To Be? 3/9/2026

    Clinical trials for central nervous system therapies face significant obstacles to approval, including subjective endpoints and complex patient selection. Consider a strategic approach for success.

  4. Tailored Approach Supports Bladder Cancer Breakthrough 3/5/2026

    Discover how a flexible operational strategy and expert site management help bladder cancer programs overcome complex logistical hurdles and achieve critical regulatory milestones.

  5. Challenges That Derail Bladder Cancer Trials And How To Anticipate Them Earlier 3/5/2026

    From the rapid evolution of standard-of-care benchmarks to the logistical strain of procedure-heavy urology workflows, the path to a successful endpoint is filled with operational friction.

  6. Inside The Payer Perspective On Cell And Gene Therapy Coverage 3/2/2026

    Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.

  7. 21% Of CGT Clinical Holds Stem From CMC Issues. What Does This Tell Us? 2/23/2026

    Cell and gene therapy (CGT) trials account for nearly 40% of all clinical holds reported by the NIH, with over 21% caused by CMC issues, often delaying approvals by over 6 months.

  8. Best Practices For Managing The Logistics And Distribution Of CGTs 2/23/2026

    Site infrastructure, formulary timelines, and storage capabilities create barriers between approval and patient access. Planning for these operational realities separates successful launches from stalled ones.

  9. Breaking Through Tumor Defenses With Next-Generation Cell Therapy 2/20/2026

    Ernexa Therapeutics CEO Sanjeev Luther shares how clinical research has revealed why certain cancers resist treatment and how emerging cell therapies may help break through those defenses.

  10. Develop A Comprehensive Strategy For Implementing AI & Multi-Omics 2/19/2026

    Discover how a strategy-first approach to AI and multi-omics transforms complex biological data into actionable clinical decisions and more precise, targeted oncology therapies for 2026 and beyond.